P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM). (23rd June 2022)

• Record Type: Journal Article
• Authors: Dimopoulos, M.; Opat, S.; D'Sa, S.; Jurczak, W.; Lee, H.-P.; Cull, G.; Owen, R. G.; Marlton, P.; Wahlin, B. E.; Garcia-Sanz, R.; McCarthy, H.; Mulligan, S.; Tedeschi, A.; Castillo, J. J.; Czyz, J.; Fernandez De Larrea Rodriguez, C.; Belada, D.; Libby, E.; Matous, J.; Motta, M.; Siddiqi, T.; Tani, M.; Trneny, M.; Minnema, M.; Buske, C.; Leblond, V.; Treon, S. P.; Trotman, J.; Chan, W. Y.; Schneider, J.; Allewelt, H.; Cohen, A.; Huang, J.; Tam, C. S.;
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 1048
• Page End: 1049
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000847512.47964.b7
• Languages: English
• ISSNs: 2572-9241